MULTIMODALITY THERAPY FOR ADENOCARCINOMA OF THE ESOPHAGUS

被引:39
作者
NAUNHEIM, KS
PETRUSKA, PJ
ROY, TS
SCHLUETER, JM
KIM, H
BAUE, AE
机构
[1] Division of Cardiothoracic Surgery, St. Louis University Health Sciences Center, St. Louis, MO
关键词
D O I
10.1016/0003-4975(95)00119-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Few reports exist detailing results of multimodality treatment for adenocarcinoma of the esophagus. We have treated 28 such patients using a preoperative regimen consisting of two courses of cisplatin and 5-fluorouracil with radiation (either 3,000 or 3,600 cGy). There were 25 men and 3 women (mean age, 62.9 years; range, 35 to 86 years), and 16 patients were known to have Barrett's esophagus. Dysphagia was present for a mean of 2.7 months, and the average weight loss was 6.5 kg. Tumors ranged from 2 to 10 cm in length (mean, 5.2 +/- 1.8 cm) with American Joint Committee on Cancer clinical stage I in 2 patients, stage II in 19 patients, and stage III in 7. Dysphagia improved in 23 patients (82%), and in 8 (29%) no tumor was detected during radiologic and endoscopic staging after neoadjuvant therapy. Four patients refused operation. Esophagectomy via standard Ivor Lewis approach was accomplished in 20 of 24 patients (87%) undergoing operation. There were no operative deaths, and mean hospital stay was 15.5 +/- 11.6 days. Four patients (17%) were complete responders with no tumor in the resected specimen. Actuarial survival in the 28 patients at 1, 2, and 3 years is 71%, 28%, and 20% respectively. Of the 20 esophagectomy patients, 6 are alive with no evidence of disease at 10, 50, 54, 70, 77, and 84 months. Three of these were complete responders. Only 1 of the 8 patients not undergoing resection is alive at 16 months with no evidence of disease after further radiotherapy and chemotherapy. These data suggest that preoperative combined modality therapy for adenocarcinoma of the esophagus is safe and effective treatment. It results in excellent symptomatic improvement, a complete response rate of 17%, and a significant chance for long-term survival.
引用
收藏
页码:1085 / 1091
页数:7
相关论文
共 27 条
[1]   EVALUATION OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY FOR RESECTABLE ADENOCARCINOMA OF THE ESOPHAGUS OR GASTROESOPHAGEAL JUNCTION [J].
AJANI, JA ;
ROTH, JA ;
RYAN, B ;
MCMURTREY, M ;
RICH, TA ;
JACKSON, DE ;
ABBRUZZESE, JL ;
LEVIN, B ;
DECARO, L ;
MOUNTAIN, C .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1231-1238
[2]  
ARNOTT SJ, 1993, RADIOTHER ONCOL, V24, P108
[3]  
BEAHRS OH, 1988, MANUAL STAGING CANC, P63
[4]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[5]  
CAREY RW, 1991, CANCER, V68, P489, DOI 10.1002/1097-0142(19910801)68:3<489::AID-CNCR2820680307>3.0.CO
[6]  
2-M
[7]   LONG-TERM RESULTS OF INFUSIONAL 5-FU, MITOMYCIN-C, AND RADIATION AS PRIMARY MANAGEMENT OF ESOPHAGEAL-CARCINOMA [J].
COIA, LR ;
ENGSTROM, PF ;
PAUL, AR ;
STAFFORD, PM ;
HANKS, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (01) :29-36
[8]  
FOK M, 1993, SURGERY, V113, P138
[9]   CONCURRENT CHEMOTHERAPY AND RADIATION-THERAPY FOLLOWED BY TRANSHIATAL ESOPHAGECTOMY FOR LOCAL-REGIONAL CANCER OF THE ESOPHAGUS [J].
FORASTIERE, AA ;
ORRINGER, MB ;
PEREZTAMAYO, C ;
URBA, SG ;
HUSTED, S ;
TAKASUGI, BJ ;
ZAHURAK, M .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :119-127
[10]  
GALANDIUK S, 1989, ANN SURG, V203, P101